Clinical Trials Browser

Interventional × Recurrence × selicrelumab × Clear all

NCT02225002 2018-08-28

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Phase 1 Completed

Recurrence